859. Suboptimal Uptake, Retention, and Adherence of Daily Oral PrEP Among People with OUD Receiving HCV Treatment

Autor: Brokus, Christopher J, Stevens, Jasmine, Silk, Rachel, Mount, Julia, Gannon, Catherine, Eyasu, Rahwa, Davis, Ashley, Cover, Amelia, Ebah, Emade, Gayle, Britt, Ogbumbadiugha-Weekes, Onyinyechi, Narayanan, Shivakumar, Bijole, Phyllis, Jones, Miriam, Kier, Randy, Sternberg, David, Masur, Henry, Kottilil, Shyam, Kattakuzhy, Sarah, Rosenthal, Elana S

Publikováno v: Open Forum Infectious Diseases

Background Daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) effectively prevents HIV among people who use drugs (PWUD). Despite rising rates of HIV incidence and injection drug use, PrEP use remains low and limited re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aada1aaede550fe23a58441ca1ff8c5
https://doi.org/10.1093/ofid/ofab466.1054

Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment.

Autor: Brokus C; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Kattakuzhy S; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Gayle B; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Narayanan S; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Davis A; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Cover A; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Eyasu R; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Ebah E; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Ogbumbadiugha-Weekes O; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Hoffmann J; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Silk R; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Stevens J; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Mount J; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Gannon C; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Nussdorf L; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA., Mathur P; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Bijole P; HIPS, Washington, District of Columbia, USA., Jones M; HIPS, Washington, District of Columbia, USA., Kier R; HIPS, Washington, District of Columbia, USA., Sternberg D; HIPS, Washington, District of Columbia, USA., Greenblatt A; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.; Department of Family and Community Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA., Weintraub E; Division of Addiction Research and Treatment, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA., Masur H; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA., Kottilil S; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Rosenthal E; DC Partnership for HIV/AIDS Progress, Washington, District of Columbia, USA.; Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2021 Dec 29; Vol. 9 (3), pp. ofab658. Date of Electronic Publication: 2021 Dec 29 (Print Publication: 2022).